Association of Angiotensin II–Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess whether angiotensin II-stimulating antihypertensives (thiazides, dihydropyridine calcium channel blockers, and angiotensin I receptor blockers) convey a lower risk of incident dementia compared to angiotensin II-inhibiting antihypertensives (angiotensin-converting enzyme inhibitors, β-blockers, and nondihydropyridine calcium channel blockers), in accordance with the "angiotensin hypothesis." METHODS: We performed Cox regression analyses of incident dementia (or mortality as competing risk) during 6-8 years of follow-up in a population sample of 1,909 community-dwelling individuals (54% women) without dementia, aged 70-78 (mean 74.5 ± 2.5) years. RESULTS: After a median of 6.7 years of follow-up, dementia status was available for 1,870 (98%) and mortality for 1,904 (>99%) participants. Dementia incidence was 5.6% (27/480) in angiotensin II-stimulating, 8.2% (59/721) in angiotensin II-inhibiting, and 6.9% (46/669) in both antihypertensive type users. Adjusted for dementia risk factors including blood pressure and medical history, angiotensin II-stimulating antihypertensive users had a 45% lower incident dementia rate (hazard ratio [HR], 0.55; 95% CI, 0.34-0.89) without excess mortality (HR, 0.86; 95% CI, 0.64-1.16), and individuals using both types had a nonsignificant 20% lower dementia rate (HR, 0.80; 95% CI,0.53-1.20) without excess mortality (HR, 0.97; 95% CI, 0.76-1.24), compared to angiotensin II-inhibiting antihypertensive users. Results were consistent for subgroups based on diabetes and stroke history, but may be specific for individuals without a history of cardiovascular disease. CONCLUSIONS: Users of angiotensin II-stimulating antihypertensives had lower dementia rates compared to angiotensin II-inhibiting antihypertensive users, supporting the angiotensin hypothesis. Confounding by indication must be examined further, although subanalyses suggest this did not influence results. If replicated, dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationWilliamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies
Haneuse, S., VanderWeele, T. J., & Arterburn, D. (2019) · JAMA · doi:10.1001/jama.2018.21554 · Cited by 988
van Charante, E. P. M., Richard, E., Eurelings, L. S., van Dalen, J.-W., Ligthart, S. A., van Bussel, E. F., Hoevenaar-Blom, M. P., Vermeulen, M., & van Gool, W. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30950-3 · Cited by 611
Self-citationDefining the relationship between hypertension, cognitive decline, and dementia: a review
Walker, K. A., Power, M. C., & Gottesman, R. F. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0724-3 · Cited by 394
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · cited 2×
“Furthermore, angiotensin- converting enzyme mediates β-amyloid (Aβ) degradation in the brain.(16,25) Based on these effects, drugs that increase angiotensin II–mediated activity at the AT2 and AT4 receptors (angiotensin II–stimulating) may provide brain protection compared to those decreasing activity at these recepto…”
BackgroundKronish (2011) · doi:10.1161/circulationaha.110.983874 · Cited by 182
Kehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133 · cited 7×
“Furthermore, angiotensin- converting enzyme mediates β-amyloid (Aβ) degradation in the brain.(16,25) Based on these effects, drugs that increase angiotensin II–mediated activity at the AT2 and AT4 receptors (angiotensin II–stimulating) may provide brain protection compared to those decreasing activity at these recepto…”
BackgroundResultInfluentialRichard, E., Andrieu, S., Solomon, A., Mangialasche, F., Ahtiluoto, S., van Charante, E. P. M., Coley, N., Fratiglioni, L., Neely, A. S., Vellas, B., et al. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.06.012 · Cited by 121 · cited 1×
“Trials comparing antihypertensive subclasses with dementia as primary outcome are challenging, requiring many participants and long follow-up.(48) Designing intervention and control conditions is also problematic, since withholding antihypertensive treatment is unethical, several subclasses potentially reduce dementia…”
BackgroundSelf-citation
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Hypertension, Neurovascular Dysfunction, and Cognitive Impairment
Santisteban, M. M., Iadecola, C., & Carnevale, D. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.18085 · Cited by 279
Metadata
- Authors
- van Dalen, J. W., Marcum, Z. A., Gray, S. L., Barthold, D., Moll van Charante, E. P., van Gool, W. A., Crane, P. K., Larson, E. B., & Richard, E.
- Venue
- Neurology
- Published
- 2021-01-05
- Volume
- 96
- Issue
- 1
- Pages
- e67-e80
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3097116649
- Cited by
- 52
- References
- 12
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Angiotensin II–Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000010996
- The paper
- van Dalen, J. W., Marcum, Z. A., Gray, S. L., Barthold, D., Moll van Charante, E. P., van Gool, W. A., Crane, P. K., Larson, E. B., & Richard, E. (2021). Association of Angiotensin II–Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial. Neurology. https://doi.org/10.1212/wnl.0000000000010996
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.